BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Hudson B, Walker AJ, Irving WL. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. J Med Virol 2017;89:2158-64. [PMID: 28480974 DOI: 10.1002/jmv.24848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med 2018;57:951-6. [PMID: 29225269 DOI: 10.2169/internalmedicine.9671-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig 2017;37:61-70. [PMID: 27587071 DOI: 10.1007/s40261-016-0458-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
5 Mousa MHA, Ahmed NS, Schwedtmann K, Frakolaki E, Vassilaki N, Zoidis G, Weigand JJ, Abadi AH. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors. Pharmaceuticals (Basel) 2021;14:292. [PMID: 33806139 DOI: 10.3390/ph14040292] [Reference Citation Analysis]
6 Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016;65:1861-70. [PMID: 27605539 DOI: 10.1136/gutjnl-2016-312444] [Cited by in Crossref: 130] [Cited by in F6Publishing: 127] [Article Influence: 21.7] [Reference Citation Analysis]
7 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
8 Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med 2016;8:1-8. [PMID: 26889091 DOI: 10.2147/HMER.S96110] [Reference Citation Analysis]
9 Sacco R, Messina V, Gentilucci UV, Adinolfi LE, Ascione A, Barbarini G, Barlattani A, Cariti G, Cozzolongo R, Fimiani B, Francavilla R, Furlan C, Garrucciu G, Iovinella V, Rinaldi L, Marignani M, Begini P, Palitti VP, Pellicelli AM, Scifo G, Facciorusso A, Giacomelli L, Shah A, Bertino G, Perazzo S, Bresci G, Izzi A. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study. Drugs Context 2020;9:2020-4-11. [PMID: 33408749 DOI: 10.7573/dic.2020-4-11] [Reference Citation Analysis]
10 Campos Fernández de Sevilla MÁ, Gallego Úbeda M, Heredia Benito M, García-Cabrera E, Monje García B, Tovar Pozo M, Delgado Téllez de Cepeda L, Iglesias-Peinado I. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals. Int J Clin Pharm 2019;41:488-95. [PMID: 31028599 DOI: 10.1007/s11096-019-00809-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2. [PMID: 30288305 DOI: 10.1186/s41124-016-0011-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lee S, Lee SH, Lee SJ, Kim KH, Lee JE, Cho H, Lee SG, Chung JS, Kwak IS. Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea. Korean J Intern Med 2016;31:772-8. [PMID: 27117318 DOI: 10.3904/kjim.2015.353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Nagpal SJ, Kabbany MN, Mohamad B, Lopez R, Zein NN, Alkhouri N. Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation. Dig Dis Sci 2016;61:2102-7. [PMID: 26993824 DOI: 10.1007/s10620-016-4124-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 He QF, Zhang QF, Zhang DZ. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. Dig Dis Sci 2016;61:3108-17. [PMID: 27619394 DOI: 10.1007/s10620-016-4291-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ravinetto R, De Weggheleire A, Dorlo TP, Francque S, Sokkab A, Pouget C, Meessen B, Tabernero P, Newton PN, Lynen L. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Trop Med Int Health 2016;21:1490-5. [PMID: 27671365 DOI: 10.1111/tmi.12784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Dorababu A. Indole - a promising pharmacophore in recent antiviral drug discovery. RSC Med Chem 2020;11:1335-53. [PMID: 34095843 DOI: 10.1039/d0md00288g] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PLoS One. 2016;11:e0155869. [PMID: 27196673 DOI: 10.1371/journal.pone.0155869] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
18 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
19 Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10:789-798. [PMID: 27443347 DOI: 10.1007/s12072-016-9755-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 MacBrayne CE, Kiser JJ. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. Clin Infect Dis 2016;63 Suppl 1:S12-23. [PMID: 27363437 DOI: 10.1093/cid/ciw220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]